目的 系统评价纳洛酮治疗病毒性脑炎的疗效与安全性。 方法 计算机检索Medline、Cochrane图书馆、EMbase、CBM、CNKI、万方从建库至2012年2月收录的相关中英文文献，收集所有关于在抗病毒、肾上腺皮质激素以及脱水、止惊、降温等综合治疗的基础上，辅助应用纳洛酮治疗病毒性脑炎对照试验。根据纳入与排除标准筛选文献、评价质量、提取资料，采用RevMan 5.1软件进行Meta分析。 结果 共纳入5个对照试验，包括279例病毒性脑炎患者。Meta分析结果显示：纳洛酮的应用对13岁以上病毒性脑炎患者的总有效率[RR=1.15，95%（0.94，1.42），P=0.18]及死亡率[RR=0.45，95%（0.17，1.16），P=0.10]并无影响，但可以缩短退热时间[WMD=−0.85，95%（−1.74，0.03），P=0.06]、头痛消失时间[WMD=−0.40，95%（−0.55，0.25），P＜0.000 01]、抽搐停止时间[WMD=−0.87，95%（−1.09，−0.66），P＜0.000 01]、意识恢复时间[WMD=−1.10，95%（−2.05，−0.15），P=0.02]、脑膜刺激征消失时间[WMD=−0.15，95%（−0.73，0.29），P＜0.000 01]、呼衰纠正时间[WMD=−1.22，95%（−2.11，−0.33），P=0.007]及病程[WMD=−1.38，95%（−2.65，−0.11），P=0.03]。 结论 现有证据表明，纳洛酮不能提高病毒性脑炎的疗效，但对改善症状有一定帮助。受本系统评价纳入研究数量和质量的限制，上述结论尚需更多高质量的随机对照试验验证。
Objective To assess the efficacy and safety of adalimumab on plaque psoriasis. Methods We searched the MEDLINE (1966 to December 2009), Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 12, 2009), EMbase (1980 to December 2009), CBM (1978 to December 2009), and CNKI (1979 to December 2009) to collect randomized controlled trials (RCTs) of adalimumab for plaque psoriasis. The language was confined to English and Chinese. We screened the retrieved studies according to the predefined inclusion and exclusion criteria, evaluated the quality of included studies, and performed meta-analyses by using the Cochrane Collaboration’s RevMan 4.2 software. Results Three RCTs involving 1?630 patients with chronic moderate or severe plaque psoriasis were included and assessed. At the end of 4th, 8th, 12th and 16th week, the PASI 75s of subcutaneous injection every other week in adalimumab (EOW) group were obviously higher than that of placebo group and methotrexate group. While at the end of 24th week and 60th week, the PASI 75s showed no difference between adalimumab EOW and placebo group. Twelve weeks after subcutaneous injection each week with adalimumab (QW), PASI 75 was obviously higher than those of placebo and EOW groups. However, at the end of 24th week and 60th week, there was no significant difference between adalimumab QW and placebo followed by adalimumab EOW. At end of week 12-16, there was no difference between adalimumab EOW group and placebo group in the incidence of adverse effects, with the exception of pain on injection site and upper respiration viral infection. At week 12-60, there was no difference between adalimumab QW and EOW groups in the incidence of adverse effects, with the exception of all serious adverse effects. Conclusion The limited evidence indicates that subcutaneous injection of adalimumab every other week for 12-16 weeks is safe and efficient for patients with moderate or severe plaque psoriasis. The efficacy can’t be enhanced when the treatment is prolonged to 24 weeks. The once-a-week protocol has no obvious advantage over every other week protocol. More RCTs are required to verify these conclusions owing to the limitations of the present study.